The advances in medical practice since World War II have been stunning, and they continue apace. Some of the existing and anticipated ones are discussed here and in Part 2.
The blockbuster weight-loss drugs Wegovy and Ozempic have helped many patients rapidly slim down. But these powerful pharmaceuticals could have unintended consequences we may not be ready for. Meanwhile, what motivates people to wear masks? Post COVID, researchers are finally beginning to find some answers.
Wegovy and Ozempic, both GLP-1 agonists, have taken the world by storm, providing a simple way to lose weight without changing our lifestyle. A new report in Science helps us understand what we do not know: the known unknowns of obesity. Let me summarize.
The two long-term drivers for weight loss and control are your basal metabolic rate, the number of calories you burn while your carcass is at rest, and your muscle tissue’s ability to perform and sustain physical activity for extended periods moving your carcass. Both are dependent on the amount of muscle tissue you have developed through conditioning or granted through genetics. So, before you decide to withdraw from your 401K to pay for your hit of Wegovy or Ozempic or any other miraculously pitched expensive weight loss drug, you need to consider some basic physiology.
Ozempic, a drug indicated for Type II diabetes, has become the latest weight-loss darling. Not since ivermectin has a drug gained so much interest from its off-label uses. Let’s take a deeper look at the science and a regulatory conundrum.